Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Americans are getting slimmer. The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that: ...

Direct-to-consumer healthcare startup Ro announced Wednesday that its platform will now offer cheaper single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lillywhich ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the ...

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...

The FDA has announced that popular weight loss medication ... of the drug from the market by early 2025. Tirzepatide is the active ingredient in Eli Lilly's drugs Mounjaro and Zepbound, branded ...

Zepbound got FDA approval to treat obesity and weight loss in November 2023, joining Eli Lilly's other tirzepatide-based drug, Mounjaro. The two drugs, along with Novo Nordisk's (NVO) Ozempic and ...